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Research
During the last several years, the incidences of 
prostate and testicular cancer have increased 
significantly. By 50 years of age, about 50% 
of all men will suffer from prostatic hyper­
plasia (Berry et al. 1984). It has been demon­
strated that exposure to androgens, such as 
dihydrotestosterone (DHT), increases the risk 
for the development of prostate cancer (Carson 
and Rittmaster 2003). There have also been 
reports of masculinization of animals and wild­
life populations (Ellis et al. 2003). The increase 
in prostate cancer and the recorded masculini­
zation of animals indicate that there are com­
pounds in the environment with androgenic 
properties. This has led to research focused on 
the identification of substances with poten­
tial AR agonistic properties by screening large 
numbers of environmental compounds (Fang 
et al. 2003; Kojima et al. 2004; Sohoni and 
Sumpter 1998). These studies led to the iden­
tification of several estrogen receptor (ER) ago­
nists as being androgen antagonists. However, 
although an earlier study demonstrated that 
2­tert­butylanthraquinone and benzoanthrone 
may act as weak agonists to the human andro­
gen receptor (hAR) at high concentrations 
(Araki et al. 2005), only recently did our group 
identify the brominated flame retardant (BFR) 
1,2­dibromo­4­(1,2 dibromo  ethyl)cyclohexane 
(TBECH) as the first environmental chemi­
cal to bind to and activate the hAR with high 
potency (Larsson et al. 2006). AR is activated 
through binding of a ligand, such as testos­
terone or DHT, to its ligand­binding domain 
(LBD), followed by dis  sociation of inhibi­
tory heat­shock proteins. After activation, the 
AR–ligand complex migrates into the nucleus 
and binds to its response element, which 
together with coactivators initiates transcrip­
tion and cellular responses (Brinkmann et al. 
1999; Veldscholte et al. 1992).
Because of the four chiral carbons pres­
ent in its structure, TBECH can exist in four 
diastereo  isomeric forms (α, β, γ, and δ). The 
α and β forms are found in the commercial 
flame retardant Saytex BCL 462 (Albemarle 
Corp., Baton Rouge, LA, USA), whereas the 
γ and δ forms are converted from α and β at 
temperatures > 120°C (Arsenault et al. 2008). 
In 2002, TBECH was reportedly produced 
at volumes between 4 and 225 metric tons 
[U.S. Environmental Protection Agency (EPA) 
2002]. TBECH was reported to be mutagenic 
in a study that tested 27 different chemicals 
using a L5178Y tk+/tk– mouse lymphoma­
cell forward­mutation assay (McGregor et al. 
1991). In 1995, TBECH was found to be 
present in industrial waste water near Haifa, 
Israel (Santillo et al. 1997), and more recent 
studies have reported the presence of TBECH 
in beluga whales in the Canadian Arctic 
(Tomy et al. 2008). In a recent study using 
zebrafish, Nyholm et al. (2008) showed that 
TBECH can be maternally transferred; they 
speculated that higher levels of TBECH would 
be found in the offspring of species that invest 
more lipids in their eggs, which is in line with 
the recent discovery of TBECH in eggs from 
herring gulls and double­crested cormorants 
(Gauthier et al. 2009).
In the present study, we analyzed the inter­
action energies between the different TBECH 
diastereomers and the hAR in silico and deter­
mined their potential to bind and activate the 
receptor and its downstream target, prostate­
specific antigen (PSA) in vitro.
Materials and Methods
Chemicals. We synthesized TBECH diastere­
omers as previously described (Arsenault et al. 
2008). DHT and testosterone were purchased 
from Sigma Aldrich (St. Louis, MO, USA). 
TBECH­αβ and TBECH­β were dissolved 
with dichloromethane that was allowed to 
evaporate after addition of dimethyl sulfoxide 
(DMSO). All other ligands were dissolved in 
DMSO. Exposure of cells was performed in 
cell culture media with a maximum of 0.1% 
DMSO present.
Computational modeling. We determined 
the interaction energies between the ligand 
and the AR ligand­binding site using the 
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Ba c k g r o u n d: Reported incidences of prostate cancer and masculinization of animals indicate a 
release of compounds with androgenic properties into the environment. Large numbers of environ-
mental pollutants have been screened to identify such compounds; however, not until recently was 
1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane (TBECH) identified as the first potent activator of the 
human androgen receptor (hAR). TBECH has been found in beluga whales and bird eggs and has also 
been found to be maternally transferred in zebrafish.
oBjectives: In the present study we investigated interaction energies between TBECH diastere-
omers (α, β, γ, and δ) and the hAR, and their ability to activate the receptor and induce prostate-
specific antigen (PSA) expression in vitro.
Me t h o d s : We performed computational modeling to determine interaction energies between the 
ligand and the AR ligand-binding site, and measured in vitro competitive binding assays for AR by 
polarization fluorometry analysis. We used enzyme-linked immunosorbent assays to determine PSA 
activity in LNCaP and HepG2 cells. 
re s u l t s: We found the γ and δ diastereomers to be more potent activators of hAR than the α and β 
diastereomers, which was confirmed in receptor binding studies. All TBECH diastereomers induced 
PSA expression in LNCaP cells even though the AR present in these cells is mutated (T877A). 
Modeling studies of LNCaP AR revealed that TBECH diastereomers bound to the receptor with a 
closer distance to the key amino acids in the ligand-binding domain, indicating stronger binding to 
the mutated receptor.
co n c l u s i o n s: The present study demonstrates the ability of TBECH to activate the hAR, indicat-
ing that it is a potential endocrine disruptor.
key w o r d s : androgen, brominated flame retardant, endocrine disruptor. Environ Health Perspect 
117:1853–1859 (2009).  doi:10.1289/ehp.0901065 available via http://dx.doi.org/ [Online 3 August 
2009]Khalaf et al.
1854  v o l u m e  117 | n u m b e r 12 | December 2009  •  Environmental Health Perspectives
Molecular Operating Environment (MOE) 
program (Chemical Computing Group, Köln, 
Germany). The crystal structure of the hAR 
obtained from the Protein Data Bank entry 
1e3g (PDB 2009) was subjected to minimiza­
tion using the Amber99 force field embed­
ded in MOE, and the minimized structure 
was used as template for dockings with all 
ligands. Before docking, the ligand­binding 
site was determined using the MOE Alpha 
Site Finder. We performed the dockings as 
Monte Carlo–simulated annealing­based flex­
ible docking of the ligands into the receptor, 
using the automated docking as incorporated 
in MOE. Each evaluated system was set to a 
maximum of 500 confirmed dockings, where 
the docked structures were sorted based on the 
lowest S­value (the objective function, based 
on evaluating the affinity ΔG scoring func­
tion, which is a combination of strain energy 
and mutual similarity score). Before calcula­
tion of interaction energies, the docked struc­
tures were subjected to relaxation, molecular 
dynamics simulations, and additional relax­
ation as previously described (Larsson et al. 
2006). The AR from LNCaP cells (a prostate 
cancer cell line) harbors a mutation (T877A) 
in the ligand­binding pocket (LBP), so the 
LNCaP AR was modeled using the crystal 
structure of the hAR as a template, as pre­
viously described (Larsson et al. 2006). The 
model was generated as a Cartesian average of 
10 models and minimized using the Amber99 
force field. When this was done, the LNCaP 
AR model was used for docking simulations in 
the same manner as the hAR.
Competition assay. We performed com­
petitive binding assays for AR using the 
PolarScreen AR competition assay (PanVera, 
Madison, WI, USA) according to the manu­
facturer’s instructions, using polarization fluo­
rometry analysis, with excitation at 485 nm 
and emission at 535 nm, on a GeniosPro 
instrument (Tecan Trading AG, Männedorf, 
Switzerland). The AR­LBD used in the 
PolarScreen AR competition assay is derived 
from rat but shows 100% sequence homology 
to the hAR: The amino acid sequences of the 
LBDs of rat and human AR [GeneBank acces­
sion numbers J05454 and M20132 (National 
Center for Biotechnology Information 2009), 
respectively] are identical. The final concen­
tration of AR LBD was 50 nM. Binding 
affinity was determined using competition 
against the synthetic androgen Fluormone 
AL Green ligand (2 nM; Invitrogen). DHT 
was used as a positive control. We produced 
competition curves for DHT and TBECH 
  diastereomers using concentrations ranging 
from 1 nM to 10 µM. All analyses were per­
formed in   triplicate.
Cell culture, transfection, and stimula-
tion. HepG2 hepatocellular carcinoma cells 
were cultured in Eagle minimal essential 
medium (E­MEM; Invitrogen) supplemented 
with 10% fetal calf serum (FCS; HyClone; 
Nordic Biolabs, Taby, Sweden), 1 mM 
sodium pyruvate (Invitrogen), 0.1 mM non­
essential amino acids (Biochrom AG, Berlin, 
Germany), and 1% antibiotic antimycotic 
mixture (Invitrogen) in an incubator at a sta­
ble environment of 95% humidity, 5% CO2, 
and 37°C.
Before transfection, the cells were seeded 
onto 24­well plates in an antibiotic­free and 
phenol­free medium complemented with 
charcoal­stripped FCS. The charcoal­stripped 
serum was prepared by mixing serum with 
activated charcoal and Dextran T­70 (Sigma­
Aldrich Sweden AB, Stockholm, Sweden). 
After 12 hr incubation at 4°C, the mixture was 
centrifuged to remove the charcoal/  dextran, 
and the supernatant was filter­sterilized. At 
90–95% confluence, the cells were transfected 
with 270 ng slp­ARE­Luc (sex­limiting pro­
tein–androgen response element–luciferase) 
reporter, 270 ng hAR expression vector 
(pCMVhAR), and 60 ng Renilla luciferase 
(pRL; Promega, Madison, WI, USA) using 
Lipofectamine 2000 (Invitrogen) according 
to the manufacturer’s recommendations. The 
slp­ARE­Luc vector contains four copies of 
an ARE that has been shown to be specific for 
AR activation while minimizing the influence 
of glucocorticoids (Verrijdt et al. 2002). At 
24 hr post  transfection, the medium was aspi­
rated and replaced with medium containing 
different concentrations DHT, testosterone, 
or different diastereomers of TBECH. After 
exposure (8 hr for testosterone and DHT, 
40 hr for TBECH), the cells were lysed in situ 
using passive lysis buffer (Promega), and 
luciferase levels were meas  ured using the Dual 
Luciferase Assay Kit (Promega) in a TD 20/20 
luminometer (Turner Designs, Sunnyvale, 
CA, USA). The luciferase values were normal­
ized to the corresponding Renilla values. All 
analyses were performed in triplicate.
Enzyme-linked immunosorbent assay 
(ELISA). For the ELISA, human LNCaP cells 
were cultured in culture flasks in E­MEM 
(Invitrogen) supplemented with 10% FCS, 
1 mM sodium pyruvate, 0.1 mM nonessential 
amino acids, and 1% antibiotic antimycotic 
mixture in an incubator at a stable environ­
ment of 95% humidity, 5% CO2, and 37°C. 
Before challenge, the cells were seeded onto 
24­well plates in cell culture media containing 
charcoal­stripped serum.
LNCaP cells were challenged with 
100 nM DHT or different combinations of 
the TBECH diastereomers at 1 µM. The cells 
were challenged for 5 days; the super  natants 
were collected by gentle pipetting and stored 
at –80° C until use. PSA quantification was 
performed by coating each well, in 96­well 
plates, with 100 µL of a 1:1 mix of sample 
and coating buffer (0.1 M sodium carbonate, 
Figure 1. The molecular structures of the BFRs examined, along with structures of DHT and testosterone for 
comparison. (A) TBECH-α {rac-(1R,2R)-1,2-dibromo-(4S)-4-[(1R)1,2-dibromoethyl]cyclohexane}. (B) TBECH-β 
{rac-(1R,2R)-1,2-dibromo-(4S)-4-[(1S)1,2-dibromoethyl]cyclohexane}. (C) TBECH- γ {rac-(1R,2R)-1,2-dibromo-
(4R)-4-[(1R)1,2-dibromoethyl]cyclohexane}. (D) TBECH-δ {rac-(1R,2R)-1,2-dibromo-(4R)-4-[(1S)1,2-dibromo-
ethyl]cyclohexane}. (E) DHT. (F) Testosterone. 
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pH 9.6) followed by incubation for 1 hr at 
room temperature. To obtain a standard 
curve, serial dilutions of human PSA (Sigma, 
St. Louis, MO, USA) were prepared, loaded 
onto the plates, and treated like the samples. 
The buffer was aspirated, and each well was 
washed 3 times with 300 µL wash buffer 
[phosphate­buffered saline (PBS) with 0.05% 
Tween­20, pH 7.4]. This was followed by the 
addition of 200 µL blocking buffer (PBS with 
5% bovine serum albumin) and incubation 
for 1 hr at room temperature. The plates were 
then washed 3 times with 300 µL wash buffer 
and incubated with 100 µL primary antibody 
(anti­human PSA; Sigma) for 1 hr at room 
temperature. The plates were washed and incu­
bated with 100 µL secondary antibody (ECL 
anti­rabbit, horseradish peroxidase–linked 
whole antibody (Amersham Biosciences, Little 
Chalfont, Buckinghamshire, UK) for 30 min at 
room temperature. Detection was performed 
by adding 100 µL 1­Step Turbo TMB­ELISA 
(Pierce, Rockford, IL, USA) for 30 min. The 
reaction was stopped with 50 µL 1 M H2SO4, 
and the absorbance was measured at 450 nm 
using a Multiskan MS plate reader (Thermo 
Labsystems, Vantaa, Finland). 
Statistical analysis. Statistical significant 
differences were determined using two­tailed 
Student’s t­test.
Results
Ligand docking. We determined ligand dock­
ing of TBECH in hAR and LNCaP AR LBD 
using molecular modeling techniques. The 
BFR TBECH can exist as four diastereomers 
(α, β, γ, and δ), which differ in the manner in 
which the bromine atoms are oriented in their 
molecular structures (Figure 1). These differ­
ent orientations of the bromine atoms in the 
molecule strongly affect their binding affinities 
in the AR LBD.
Docking simulations established that all 
four TBECH diastereomers occupied the 
same hAR LBP as did DHT (Figure 2A). 
In the LNCaP AR, the structure of the LBP 
Figure 2. The four key amino acids (N705, Q711, R752, and T877/A877) in the active site of the hAR (A) and LNCaP AR (B) shown with the natural ligands DHT, tes-
tosterone (T), and the four TBECH diastereomers (C and D). The closest distances between the amino acids and the ligands for hAR (C) and for LNCaP AR (D). See 
“Materials and Methods” for details of simulations. 
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differs from the hAR because of the T877A 
mutation. This mutation shortens the distance 
between ligands and Ala877 in the LBP with 
a concomitant reduction of ligand discrimina­
tion (Figure 2B). The differences in distance 
between the key amino acids [Asn705 (N705), 
Gln711 (Q711), Arg752 (R752), Thr877 
(T877), and Ala877 (A877)] and ligands are 
shown in Figure 2C and D. 
Ligand–receptor interaction energies. The 
substantial differences in distances between the 
amino acids in the LBP and ligand observed 
for the four TBECH diastereomers mani­
fested as significant differences in interaction 
energies. The natural ligands DHT and tes­
tosterone bound to the hAR with interaction 
energies of –53.8 and –48.9 kcal/mol, respec­
tively (Table 1). Among the four TBECH 
diastereomers, TBECH­δ displayed the closest 
similarities to DHT (Table 2, Figure 2C). The 
LBP inter  action energy with TBECH­δ was 
–40.1 kcal/mol, whereas those for TBECH­α, 
­β, and ­γ were –34.8, –26.8, and –35.3 kcal/
mol, respectively. Interaction of DHT and 
TBECH diastereomers with the key amino 
acids in the hAR LBD are shown in Figure 2A 
and C. In the LNCaP AR, the mutation 
T877A resulted in increased interaction ener­
gies, which suggest stronger inter  actions with 
the key amino acids in the mutated receptor 
(Tables 1 and 2, Figure 2B,D).
Competition assays. We tested the different 
diastereomers of TBECH for receptor binding 
affinity using the PolarScreen AR competi­
tive assay. In contrast to TBECH­β, TBECH 
diastereomers α, γ, and δ cannot be isolated; 
this prompted analysis of combinations of these 
in the receptor binding assay. We determined 
the binding affinity using competition against 
dexa  methasone, (Figure 3). In this assay, DHT 
had a half­maximal inhibi  tory concentration 
(IC50) of 21.5 nM with a goodness of fit (R2) 
of 0.91. The relative affinity of the TBECH 
diastereomers was 655 nM (R2 = 0.96) for 
TBECH­β, 191 nM (R2 = 0.97) for a 50:50 
mixture of TBECH­α and ­β (TBECH­αβ), 
47.4 nM (R2 = 0.98) for a 50:50 mixture of 
TBECH­γ and ­δ (50:50 TBECH­γδ), and 
35.9 nM (R2 = 0.99) for a 25:75 mixture of 
TBECH­γδ. This indicates that TBECH­γδ 
binds AR with an affinity very similar to that of 
DHT, whereas TBECH­β has the lowest affin­
ity of the TBECH diastereomers (Figure 3).
AR activation assays. We determined the 
activation capacity of the different TBECH 
diastereomers using trans  activa  tion studies in 
HepG2 and LNCaP cells. We used HepG2 
cells to allow comparison with an earlier study 
(Larsson et al. 2006), and we used LNCaP 
cells because they contain an AR mutation 
that is frequently seen in prostate cancer. 
Before exposure, the cells were transfected 
with the slp­ARE­Luc reporter vector and the 
hAR expression vector pCMVhAR together 
with an internal control (pRL). We used the 
slp­ARE­Luc vector because it contains four 
copies of an ARE that is highly specific for AR 
inter  actions. The optimal time and concentra­
tion of exposure was determined for DHT, 
testosterone, and different combination of the 
TBECH diastereomers β, 50:50 αβ, 50:50 
γδ, and 25:75 γδ.
Stimulation of HepG2 cells with testoster­
one and DHT resulted in maximal induction 
after 8–12 hr of exposure (Figure 4A), whereas 
the TBECH­γδ diastereomers (both 50:50 
and 25:75) showed a slower response with 
maximal induction after 24 hr (Figure 4B). 
DHT was also a stronger inducer than was 
testosterone, which required 10­fold higher 
concentrations (100 nM) to induce hAR acti­
vation to the same level as DHT.
AR activity decreased after further stimu­
lation at 24 hr and 48 hr, suggesting early 
activation and fast cellular metabolism of 
DHT. We also assessed the time­dependent 
AR activation in response to different com­
binations of TBECH­γδ (50:50 and 25:75) 
using a final concentration of 1 µM. The two 
TBECH­γδ combinations activated the AR 
Table 2. Interaction energies and distances between the ligand and the key amino acids of the LNCaP AR 
(T877A) determined using the MOE program.
Ligand
LNCaP AR 
interaction Ligand–amino acid distance (Å)
energy (kcal/mol) N705 Q711 R752 A877
TBECH-α –37.6 4.43 4.00 5.27 5.41
TBECH-β –41.2 5.20 3.89 6.62 5.47
TBECH-γ –49.0 3.75 3.48 5.43 4.46
TBECH-δ –43.0 3.75 3.37 4.22 4.27
DHT –63.0 2.26 4.31 2.94 4.08
Testosterone –82.5 2.84 3.32 2.73 4.73
Table 1. Interaction energies and distances between the ligand and the key amino acids of the hAR 
determined using the MOE program.
Ligand
hAR interaction 
energy (kcal/mol)
Ligand–amino acid distance (Å)
N705 Q711 R752 T877
TBECH-α –34.8 3.41 6.58 8.35 6.87
TBECH-β –26.8 2.89 7.50 12.59 3.03
TBECH-γ –35.3 4.10 4.60 6.04 3.26
TBECH-δ –40.1 4.05 5.72 4.33 3.37
DHT –53.8 2.07 1.87 3.93 1.58
Testosterone –48.9 3.37 7.51 6.16 3.36
Figure 3. Competition curves for binding of DHT 
50:50 TBECH-γδ, 50:50 TBECH-αβ, and purified 
TBECH-β to the rat AR. The amino acid sequences 
of the LBDs of rat and human AR are identical, so 
the results can be extrapolated to hAR. Each value 
represents the mean of three assays. 
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equally. Activation of AR reached statistical 
significance after 2 hr and maximal induction 
after 24 hr (Figure 4B).
To determine the optimal concentrations 
of DHT and TBECH isoforms for AR activa­
tion, we stimulated HepG2 cells with DHT 
in a dose­dependent manner for 8 hr and 
with TBECH for 40 hr. Exposure to 50:50 
TBECH­γδ resulted in a half­maximal effective 
concentration (EC50) of 14.9 nM (R2 = 0.96), 
whereas exposure to 25:75 TBECH­γδ 
resulted in an EC50 of 22.7 nM (R2 = 0.94; 
Figure 5). This suggests that TBECH­γ may 
be a better inducer of AR than TBECH­δ. 
Both of these diastereomers induce AR at con­
centrations that are comparable to those of 
DHT (10.5 nM; R2 = 0.92) and indicate that 
these TBECH diastereomers are highly potent 
androgen agonists. Determination of AR acti­
vation by 50:50 TBECH­αβ demon  strated 
that these diastereomers are less potent, with 
an EC50 of 174 nM (R2 = 0.94), one order of 
magnitude higher than DHT or TBECH­γδ. 
The weakest inducer of AR was TBECH­β, 
with an EC50 of 294 nM (R2 = 0.84). We also 
observed that TBECH­γ and ­δ are complete 
agonists to DHT, whereas TBECH­α and ­β 
are partial agonists because they conferred only 
partial induction. Determination of relative 
induction by the different compounds showed 
a 23.7 ± 5.0­fold induction after exposure to 
DHT, a 24.4 ± 5.1­fold induction with 50:50 
TBECH­γδ, a 25.5 ± 1.3­fold induction with 
25:75 TBECH­γδ, an 8.4 ± 1.2­fold induc­
tion with TBECH­αβ, and a 2.4 ± 0.3­fold 
induction with TBECH­β.
In vitro ELISA assays. We used LNCaP 
cells to determine the ability of TBECH to 
induce endogenous gene expression of PSA, 
a downstream target of the AR. The results 
revealed a 2.61 ± 0.15­fold induction of PSA 
after treatment with 100 µM DHT (Figure 6). 
PSA expression increased in response to all 
four TBECH diastereomer combinations in 
a dose­dependent manner. Exposure to 1µM 
of the TBECH diastereomers resulted in a 
3.11 ± 0.31­fold induction by TBECH­β, 
a 3.22 ± 0.26­fold induction by 50:50 
TBECH­αβ, 3.47 ± 0.12­fold induction by 
50:50 TBECH­γδ, and a 3.74 ± 0.17­fold 
induction by 25:75 TBECH­γδ. The equiva­
lent inducibility by the different compounds 
is in agreement with the modeling data that 
show similar distances to the key amino acids 
in the AR LBP of the mutated LNCaP AR.
Discussion
TBECH belongs to a group of BFRs that are 
found in a variety of products, for example, 
oriented strand boards, particle boards, and 
rigid foam and soft foam used in insulation 
and as stuffing in furnishings, respectively, or 
as an additive in polystyrene and polyurethane. 
The discovery of TBECH’s presence in both 
sediments and organisms (Gauthier et al. 2009; 
Nyholm et al. 2008; Santillo et al. 1997; Tomy 
et al. 2008), along with its potent activation 
of AR at nanomolar concentrations, suggests 
that these compounds constitute a serious 
threat to both humans and wildlife. Using the 
Waste Minimization Prioritization Tool, the 
U.S. EPA (2000) ranked TBECH as one of the 
10% most hazardous compounds to ecosys­
tems. TBECH is an additive flame retardant, 
blended into material during manufacturing. 
In some processes this may involve thermal 
procedures and certainly, in the event of fire, 
elevated temperatures are likely to cause an 
interconversion among the different TBECH 
diastereomers. Thus, although TBECH­β is 
the most abundant isoform, it is reasonable to 
believe that all four diastereomers are present 
and cause a threat to the environment.
A well­known characteristic of steroid 
receptors is that they bind their natural ligand 
with high specificity. Reported IC50 and EC50 
values for sex steroid receptors by their natu­
ral ligands and the aryl hydrocarbon receptor 
(AhR) by TCDD (2,3,7,8­tetrachloro  dibenzo­
p­dioxin) are listed in Table 3. Interestingly, 
when investigating substances with reported 
high endocrine­disrupting effects such as 
nonyl  phenol or bisphenol A (both are estro­
genic) and vinclozolin (an androgen antag­
onist), none of the substances, with the 
exception of TCDD, binds to or activates the 
steroid receptors by > 1% of the endogenous 
ligand (Table 4). In our study, we found DHT 
to have an IC50 of 21.5 nM, which correlates 
well with IC50 values reported in other studies 
(Table 3). When we examined the TBECH 
diastereomer binding activities, we found that 
50:50 TBECH­γδ binds to the AR with 22% 
Figure 5.  Determination  of  AR  activation  in 
response to TBECH diastereomers. HepG2 cells 
were stimulated with DHT for 8 hr or with TBECH 
diastereomers for 40 hr at concentrations rang-
ing from 1 nM to 10 µM. Both combinations of 
TBECH-γδ were more potent AR activators than 
TBECH-β or TBECH-αβ. All values were normalized 
against the controls that were arbitrarily set to 1. 
n = 4 per exposure group. 
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Table 3. IC50 and EC50 values reported for binding/
activation of steroid receptors by their natural 
ligands.
Receptor IC50 (M) EC50 (M)
ER 8.99 × 10–10a 1.76 × 10–11b 
AR 7.7 × 10–10c  3.90 × 10–10d 
PR 4.00 × 10–9e  2.30 × 10–7f
AhR 6.4 × 10–11g 4.88 × 10–11h 
ER binds 17β-estradiol, AR binds DHT, progesterone 
receptor (PR) binds progesterone, and AhR binds TCDD.
aData from Blair et al. (2000). bData from Pillon et al. 
(2005). cData from Cabeza et al. (2004). dData from Xu 
et al. (2005). eData from Viswanath et al. (2008). fData 
from Lenasi and Breskvar (2004). gData from Bonefeld-
Jørgensen et al. (2007), hData from Westerink et al. 
(2008).
Table 4. RBA of ligands for human receptors.
ER AR AhR
Compound RBA RAF RBA RAF RBA RAF
Nonylphenol 0.037a 0.00016b 0.0523c ND ND 0.0003d
o,p´-DDT 0.0014a 0.0009e 0.0149f 0.0126g ND ND
Bisphenol A 0.0077a 0.0183d 0.0018c ND ND ND
Vinclozolin < 0.0009a ND 0.0023f 0.0126g ND ND
Dieldrin 0.0019h 0.00001b ND ND ND ND
Aldrin 0.0029h ND 0.007f ND ND ND
TCDD < 0.0002g 0.00012g 0.0013g < 0.0013g 100 100
PCB 77 < 0.0003a ND ND ND ND 0.025i
Abbreviations: DDT, dichlorodiphenyltrichloroethane; ND, no relevant RBA/RAF for the ligand/receptor interaction 
has been reported to our knowledge; PCB 77, 3,3´,4,4´-tetrachlorobiphenyl; RAF, relative activation factor. ER binds 
17β-estradiol, AR binds DHT, and AhR binds TCDD. All values are reported as percentage of binding/activation and were 
calculated according to Fang et al. (2003), with the values obtained with natural ligands of each receptor set to 100%.
aData from Blair et al. (2000). bData from Pillon et al. (2005). cData from Scippo et al. (2004). dData from Bonefeld-
Jørgensen et al. (2007). eData from Legler et al. (1999). fData from Fang et al. (2003). gData from Viswanath et al. (2008)
hData from Sonneveld et al. (2005). iData from Zeiger et al. (2001). 
Figure 6. Determination of PSA expression in 
LNCaP cells treated with DHT or one of the four 
mixtures of TBECH diastereomers [TBECH-β, 50:50 
TBECH-αβ, 50:50 TBECH-γδ, or 25:75 TBECH-γδ) 
at a final concentration of 100 nM and 1 µM for 
5 days. C, control. n = 4 per exposure group. 
*p < 0.05 and #p < 0.001 (Student’s t-test). 
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of DHT’s binding affinity, whereas for 50:50 
TBECH­αβ we found a relative binding affin­
ity (RBA) of 6%. This correlated well with 
the binding and activation studies, in which 
50:50 TBECH­γδ displayed a higher activa­
tion/binding than TBECH­αβ (Figures 5 
and 6). Furthermore, comparison of activation 
potential demonstrated that both TBECH­γδ 
mixtures were was as potent as DHT at activat­
ing the hAR (Figure 5). The only other envi­
ronmental contaminant inferred to be able to 
maximally activate a ligated receptor is TCDD 
(Table 4). This indicates that the TBECH 
diastereomers are extremely potent AR agonists 
compared with other known pollutants with 
proven endocrine­disrupting effects.
Recently, TBECH was shown to be pres­
ent in beluga whales and herring gull eggs at 
nanomolar concentrations (Gauthier et al. 
2009; Tomy et al. 2008). Low­level expo­
sure to endocrine­disrupting compounds can 
induce functional, developmental, behavioral, 
and trans  generational disturbances, as shown 
after low­level exposure to the fungicide vin­
clozolin, which acts as an androgen antagonist 
in rats and mice (Anway et al. 2006, 2008; 
Elzeinova et al. 2008; Skinner et al. 2008). 
Therefore, although low­level exposure to the 
most common TBECH, TBECH­β, may not 
induce high AR activation, these compounds 
may nonetheless induce trans  generational 
effects at the observed levels.
The natural ligands testosterone and DHT 
showed maximal hAR activation already after 
8 hr (Figure 4). A recent study showed that 
HepG2 cells rapidly metabolized testosterone 
and DHT, resulting in 82% and 46% reduc­
tion, respectively, 21 hr after addition of the 
hormone (Simon and Mueller 2006). In con­
trast, determination of time­dependent hAR 
activation by TBECH indicates slower receptor 
activation and prolonged induction times, sug­
gesting that these compounds are more stable 
in this cell line. The stability of TBECH is 
further supported by the discovery of its pres­
ence in the environment (Gauthier et al. 2009; 
Tomy et al. 2008) as well as its ability to be 
maternally transferred in zebrafish (Nyholm 
et al. 2008).
Although LNCaP is an androgen­
  dependent cell line with a mutated AR 
(T877A), it retains the androgen binding 
and ligand specificity in the LBP of the AR 
(Gaddipati et al. 1994; Wang et al. 1997). This 
mutation is frequently detected and has been 
reported to be present in 30% of hormone­
refractory prostate cancer patients (Taplin et al. 
1999). PSA is a well­defined androgen­regu­
lated glycoprotein present in LNCaP cells and 
is widely used as a marker for prostate cancer 
diagnosis (Wang et al. 1997). In the present 
study, we found that both DHT and the four 
TBECH diastereomers induce comparable 
PSA expression in LNCaP cells when exposed 
to 100 nM of the compounds. TBECH­β was 
located farthest away from R752 in the hAR. 
This could explain its poor ability to activate 
the hAR. However, the LNCaP AR mutation 
(T877A) enables the different diastereom­
ers to bind with a closer distance to the key 
amino acids in the LBP, which could explain 
TBECH­β’s ability to induce PSA expres­
sion in LNCaP cells. The higher affinity of 
TBECH­β to LNCaP AR and the frequency 
of the T877A mutation suggest that these 
compounds are active in a large proportion of 
prostate tumors and that they may contribute 
to the etiology of prostate cancer.
The present study provides important data 
on the ability of TBECH to bind and acti­
vate the hAR with high affinity. Combining 
the results from the molecular modeling, the 
competition assay, and the activation assay, 
the TBECH­δ diastereomer appears to be 
the most potent, followed by TBECH­γ and 
TBECH­α, with TBECH­β being the least 
potent activator of AR. Furthermore, as the 
modeling experiments are in agreement with 
results obtained from the in vitro studies, this 
demonstrates that modeling is a powerful tool 
when identifying potential endocrine dis­
ruptors. However, it remains unknown how 
TBECH interacts with AR in other species, 
such as three­spined stickleback and zebrafish, 
that both have 11­ketotestoterone as their 
most potent activator of the AR (Hossain 
et al. 2008; Olsson et al. 2005). Therefore, 
future studies are needed to determine the 
interaction of TBECH with AR from other 
species in order to determine its effects on 
species present in the environment.
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